Incyte’s pipeline updates on Monday bring into question the value of its $750 million Escient acquisition in April 2024—and ...

The analysts said the paused trial in CSU, a medical term for hives, is the most important of the three studies ... now ...

U.S. stocks are drifting in mixed trading on Tuesday after clawing back losses from earlier in the morning. The S&P 500 was ...

WILMINGTON, Del., November 18, 2024 -- ( BUSINESS WIRE )--Incyte (Nasdaq:INCY) today announced that it will pause enrollment ...

Paris: Sanofi and Regeneron has announced that the US Food and Drug Administration (FDA) has accepted for review the ...

The company states: “Incyte (INCY) announced that it will pause enrollment in the ongoing Phase 2 study of MRGPRX2 in chronic spontaneous urticaria ... Phase 2 study evaluating MRGPRX4 in cholestatic ...

Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Incyte (INCY – Research Report) today and set a price target of $69.00.Don't ...

Incyte stock tumbled Tuesday after the company scrapped one drug and paused enrollment in the study of another.

US FDA accepts for review the resubmission of sBLA for Dupixent to treat chronic spontaneous urticaria: Paris Monday, November 18, 2024, 11:00 Hrs [IST] The US Food and Drug Admin ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activity M ...

The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...

There are dermatologists who don’t have much training in vulvar dermatology, and a lot of gyns don’t get as much training” as ...